Memantina Flas Cinfa (Memantine Hydrochloride)

• Memantine is indicated for Alzheimer’s disease, acting on the glutamatergic pathway to mitigate neuronal excitotoxicity.
• Alzheimer's disease (mild to moderate): improves cognition and daily functioning in patients with early‑stage disease.
• Alzheimer's disease (severe): helps maintain residual cognitive abilities and may reduce behavioral disturbances.

• Memantine binds to the NMDA receptor channel at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By blocking excessive calcium influx through the receptor, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, thereby supporting neuronal health in Alzheimer’s disease.

Memantine may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: temporary mental clouding.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: occurrence of convulsive episodes.
• Allergic reactions: rash, itching, swelling.
• Hallucinations: visual or auditory disturbances.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe hypotension: sudden drop in blood pressure.
• Liver enzyme elevation: abnormal hepatic function tests.

Before initiating therapy, consider the following safety measures.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes regularly.
• History of seizures: observe for increased seizure activity.
• Concurrent NMDA antagonists: avoid combined use to prevent additive toxicity.
• Pregnancy: safety not established; use only if benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantine can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid)

• Amantadine: may increase neurotoxic risk.
• Ketamine: additive NMDA antagonism can cause excessive CNS depression.
• Methylphenidate: heightened neuropsychiatric adverse effects.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may worsen cognitive deficits.
• CNS depressants (e.g., benzodiazepines): can enhance dizziness and sedation.
• Diuretics: potential for electrolyte imbalance affecting drug levels.